Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amrubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 0.57 |
| ▸ | THRB | P10828 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.57 |
| ▸ | BLM | P54132 | 8/20 | 0.57 |
| ▸ | RECQL | P46063 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.57 |
| ▸ | S100A4 | P26447 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 4/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amrubicin SCHEMBL13091911 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL10079225 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL6254801 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL10061868 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL10080133 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL868435 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL119022 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL491010 | 0.99 | CHRM1 (0.98) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL2524979 | 0.99 | CHRM1 (0.98) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL23909356 | 0.97 | CHRM1 (0.95) | CHRM1TBXA2RPTGS1ADRA1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 24048 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4727589-A1 | PROTAMINE-COATED NUCLEIC ACID/THERAPEUTIC AGENT COMPLEXES, AND USES THEREOF | The Regents of the University of California (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| US-20250367187-A1 | QUINOLINE DERIVATIVE USED FOR TREATING SMALL CELL LUNG CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2025-12-04 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20030157097-A1 | Combination therapy of an anti epidermal growth factor antibody with amrubicin | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-08-21 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1308168-A1 | NOVEL REMEDIES FOR CANCER | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-07 | — | — | EP | claimed |
| WO-2003020210-A2 | VAGINAL DELIVERY OF CHEMOTHERAPEUTIC AGENTS AND INHIBITORS OF MEMBRANE EFFLUX SYSTEMS FOR CANCER THERAPY | UMD, INC. (US) | 2003-03-13 | — | — | WO | claimed |
| US-20030049302-A1 | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy | FEMINA PHARMA INCORPORATED | 2003-03-13 | — | — | US | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| EP-1085891-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064054-A9 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999064054-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-4673668-A | ANTICANCER AGENTS | SUMITOMO PHARMACEUTICALS COMPANY (JP) | 1987-06-16 | — | — | US | claimed |